mirza kadic
The DEA has scheduled a hearing in early December to discuss the Justice Department’s proposal to reschedule marijuana to a Class III substance, a move that could delay formal action on the matter until the next presidential administration.
The agency said that after the notice of proposed rulemaking was issued, it received “numerous requests” for a hearing, which is scheduled for Dec. 2.
The Federal Register notice was posted late Monday, but won’t be formally published until Aug. 29. It was signed by DEA Administrator Anne Milgram.
Anyone interested in participating in the hearing must file a written request explaining their interest, and specifics on their objections and/or position on an issue. Milgram will then determine who will participate. She will also name a presiding officer for the hearing.
A 60-day public comment period was opened in May which led to more than 40,000 comments, of which 90% were either in favor of rescheduling or complete legalization.
Multi-state operators: Ascend Wellness (OTCQX:AAWH), Curaleaf Holdings (OTCPK:CURLF), Cresco Labs (OTCQX:CRLBF), Green Thumb Industries (OTCQX:GTBIF), Trulieve Cannabis (OTCQX:TCNNF), Ayr Wellness (OTCQX:AYRWF), Verano Holdings (OTCQX:VRNOF), and Jushi Holdings (OTCQX:JUSHF).
Cannabis ETFs: AdvisorShares Pure Cannabis ETF (YOLO), Amplify Alternative Harvest ETF (NYSEARCA:MJ), and Amplify Seymour Cannabis ETF (CNBS).
